• <tr id='2rR6wG'><strong id='2rR6wG'></strong><small id='2rR6wG'></small><button id='2rR6wG'></button><li id='2rR6wG'><noscript id='2rR6wG'><big id='2rR6wG'></big><dt id='2rR6wG'></dt></noscript></li></tr><ol id='2rR6wG'><option id='2rR6wG'><table id='2rR6wG'><blockquote id='2rR6wG'><tbody id='2rR6wG'></tbody></blockquote></table></option></ol><u id='2rR6wG'></u><kbd id='2rR6wG'><kbd id='2rR6wG'></kbd></kbd>

    <code id='2rR6wG'><strong id='2rR6wG'></strong></code>

    <fieldset id='2rR6wG'></fieldset>
          <span id='2rR6wG'></span>

              <ins id='2rR6wG'></ins>
              <acronym id='2rR6wG'><em id='2rR6wG'></em><td id='2rR6wG'><div id='2rR6wG'></div></td></acronym><address id='2rR6wG'><big id='2rR6wG'><big id='2rR6wG'></big><legend id='2rR6wG'></legend></big></address>

              <i id='2rR6wG'><div id='2rR6wG'><ins id='2rR6wG'></ins></div></i>
              <i id='2rR6wG'></i>
            1. <dl id='2rR6wG'></dl>
              1. <blockquote id='2rR6wG'><q id='2rR6wG'><noscript id='2rR6wG'></noscript><dt id='2rR6wG'></dt></q></blockquote><noframes id='2rR6wG'><i id='2rR6wG'></i>
                Global R&D

                Our global R&D resources platform is a collaboration of efforts between Hepalink R&D Center, Cytovance® Biologics CDMO R&D business teams and various third-party cooperative R&D efforts, which are capable of meeting clinical and market demands. Hepalink’s R&D center focuses on the clinical development of its own innovative drugs - heparin derivatives - and provides technical support for our commercialized pharmaceutical products. The CDMO business R&D platform, located in North America provides comprehensive development and manufacturing services for late discovery to commercial stage biologic therapeutic . We also develop a series of first-in-class drug candidates through our new drug portfolio companies, and have gradually opened clinical sites in China to join the International Multi-Center Clinical Trials (MRCT). Additionally, we are working with leading CRO providers to advance research and development drug candidates.

                ? 2020 Hepalink Group All Rights Reserved.粤ICP备11096806号-1